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A REVIEW OF BARRETT’S ESOPHAGUS
Suzanne M. Zayan PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58202-9037

Abstract
Barrett’s Esophagus is a premalignant condition that
predisposes patients to the development of esophageal
adenocarcinoma.
• Esophageal adenocarcinoma dramatically rising over several
decades; survival rates of less than 17% in a five year period.
• Management and treatment continues to evolve: use of radiofrequency ablation effective to treat low grade dysplasia
• Studies of risk factors and treatment options explored:
Efficacy and durability of endoscopic radiofrequency ablation
for treatment of low grade dysplasia as option for metaplasia
eradication
– Gastrointestinal pathologist expert reviews ensure
identification of dysplasia prior to treatment
– Appropriate endoscopic surveillance intervals
– Gastroenterology guidelines for screening and surveillance
for long term management
– Lifelong endoscopic surveillance individualized to monitor
for recurrence of metaplasia

Introduction
• Barrett's Esophagus (BE) is a pre-malignant, dysplastic
condition of the distal esophagus that predisposes patients to
the development of esophageal adenocarcinoma
• Gastroesophageal reflux disease is the precursor to the
development of BE, up to 15% of adults in the United States
have Barrett’s Esophagus.

Statement of the Problem
• Recommendations for the management and treatment of
Barrett’s esophagus continue to evolve, now expanding the use
of radio-frequency ablation (RFA) for the treatment of low grade
dysplasia BE, previously observed with endoscopic surveillance
until advancement to high grade dysplasia.
• Risk factors associated with the development of Barrett’s
esophagus need to be studied due to the increasing burden of
conditions associated with the progression to esophageal
adenocarcinoma.
• More studies are needed to evaluate the long term efficacy and
durability of early endoscopic RFA and the appropriate
surveillance intervals to further determine successful treatment
of dysplastic BE and reduction of EAC.

Research Question
• In adult patients with non-dysplastic or low grade dysplasia BE,
as compared to high grade dysplasia BE, what risk factors
predict the progression to EAC?
• In adult patients diagnosed with low grade dysplasia BE, does
earlier treatment with RFA, compared to standard intermittent
endoscopic surveillance, reduce the progression to EAC?
• In adult patients with complete eradication of Barrett’s
esophagus, what influences the recurrence of dysplastic
progression after successful RFA?

Literature Review
Review of the updated recommendations with consideration of
identified risk factors is essential to ensure adequate diagnosis
and treatment of BE considering the devastation of progression to
EAC.
• Pathophysiology of Barrett’s Esophagus
Main precursor for development of BE is a chronic reflux of
stomach acids into the lower esophagus, inducing a
premalignant condition in which normal squamous epithelial
lining of the esophagus is replaced with columnar epithelium
and goblet cells, known as intestinal metaplasia. Degrees of
neoplastic change occur during the sequence of epithelial
transition predisposing to the development of EAC.
• Risk factors for the dysplastic transitions in BE and EAC
• Wani, et al. (2011), the Barrett’s Esophagus Study (BEST),
identified risk factors for progression of LGD to EAC to include
BE length, age > 60, presence of hiatal hernia, and Caucasian
male. Pohl, et al. (2013), reported combinations of certain risk
factors influence disease progression at different times. Singh,
et al. (2014), found the grade of dysplasia, the length of the BE
segment, and the use of expert pathologists determined
progression of BE to EAC.
• Early RFA treatment in BE-LGD to reduce the progression
to EAC
• Shaheen et al. (2011), in the AIM Dysplasia Trial, found early
dysplastic BE can be successfully treated with RFA with a
durability of up to three years. The SURF study (Surveillance vs
Radiofrequency Ablation) by Phoa, et al. (2014) reported the
ablation group risk for progression to HGD/EAC was reduced by
25.0 % (95% CI, 14.1%-35.9 %; P, .001) and the risk of
neoplastic progression to EAC by 7.4% (95%CI, 0%-14.7%;
P=.03). Bulsiewicz et al. (2013) found 77% of the patients,
achieved complete eradication of intestinal metaplasia after
RFA despite the degree of dysplasia. Success of RFA depended
on healing time between RFA treatments and the length of the
BE segment.
• Determine effective follow-up endoscopic surveillance
intervals after RFA.
• Gupta, et al. (2013) analyzed data regarding return of intestinal
metaplasia after successful RFA. The median time to CRIM was
22 months with 56% in complete remission by 24 months. The
findings suggest the importance of longer term endoscopic
surveillance follow up after successful RFA in subjects with
varying degrees of BE dysplasia.

• Pasricha, et.al (2014) utilized the RFA registry to determine how
treatments with RFA and pretreatment data affected outcomes
for biopsies 12 months after the receiving RFA. CEIM was
achieved in 85% of these patients and 15% had persistent
dysplasia. During the average follow up of 2.4 years after CRIM,
IM recurred in 334 (20%) patients. Compared to patients
without recurrence, patients with recurrence after successful
CRIM, were found to be non-Caucasian, older age, have longer
BE segments, and require higher numbers of RFA treatment
sessions.

Discussion
• Several risk factors identified in the literature review influence
progression of neoplastic transition in BE. These include male
gender, advanced age, hiatal hernia, GERD, ethnicity, smoking,
poor dietary intake of fruits and vegetables, the type of
dysplasia and length of the BE segment. Accurate description
and confirmation of biopsies by a second expert pathologist, is
highly recommended.
• RFA is proven to be a successful intervention to eradicate IM.
Implementation of early treatment of BE demonstrates lower
progression rates of LGD-BE to EAC.
• There is not a confirmed number of RFA treatments that can
determine long term remission rates of BE or definitive stop
time for endoscopic surveillance.
• More studies are needed to determine long term (>5yrs)
success of early eradication of LGD.
• There is controversy between studies regarding whether the
extent and length of LGD is a predictor of progression to EAC.
Being male doubled the risk for GERD patients to develop BE
which further doubled the risk of BE patients to develop EAC.
• Evidence supports the efficacy and durability of RFA.
Predictors for success for achieving CRIM are related to
younger age and shorter initial BE segment length. Advanced
age was associated with a higher grade of BE and
advancement to EAC.
• The progression of cellular changes in BE is inconsistent, but
the risk factors associated with disease progression are clear.
Guidelines provided by various gastroenterology societies can
assist practitioners to determine patient care management for
endoscopic screening, therapy and disease surveillance.

Gastroenterology societal guidelines for screening and surveillance in Barrett’s Esophagus
Gastroenterology Society

Screening

Surveillance NDBE

Surveillance LGD

Surveillance HGD

American Gastroenterology
Association

Screen for patients with multiple risk
No dysplasia, surveillance every Low grade dysplasia: every High grade dysplasia unable to
factors: >50 yr. old, male, white race, 3-5 years
6-12 months
eradicate: every 3 months
chronic GERD, Hiatal hernia, elevated
body mass index, intra-abdominal
distribution of body fat. No screening
for general population

American Society for
Gastrointestinal Endoscopy

Consider endoscopic screening in
patients with multiple risk factors for
BE and EAC, inform patients this is not
a cancer prevention

American College of
Physicians

Consider no surveillance, or
every 3-5 yrs. with 4-quadrant
biopsies, ablation in select
cases

Confirm with GI expert;
Confirm with GI expert;
repeat EGD in 6 mo. to
Consider surveillance EGD 3
confirm LDG; Yearly
mo. in select patients;
surveillance; Endoscopic
Endoscopic resection, RFA, or
resection or ablation if
surgical consultation
warranted
Upper endoscopy in men >50 yr. old
Surveillance evaluation for men and women with history of BE; BE without dysplasia,
with chronic GERD and additional risk surveillance frequency 3-5 yr. more frequent in patients with BE and dysplasia
factors

Applicability to Clinical
Practice
• Primary care providers need to consistently identify risk factors
such as age, race, diet, tobacco, obesity and duration of GERD
symptoms when determining candidates for early endoscopic
screening for BE.
• Factors that predict the progression of non-dysplastic BE to EAC
include the initial dysplasia histology and the length of the BE
segment.
• Counsel and teach patients regarding control of modifiable risk
factors with emphasis of tobacco cessation and management of
co-morbidities.
• A diagnosis of EAC has poor survival rates. Risk stratification
can help patients make and maintain good decisions for a better
overall health outcome.
• Establish a trusting provider to patient relationship so facts
regarding BE and the risks of progression to EAC can be clearly
shared and communicated.
• Endoscopic therapy with radiofrequency ablation is now the
standard of care for treatment of dysplastic BE. It has high rates
of success and durability when used alone or in combination
with other gastric therapy.
• Follow-up should be individualized, and treatment decisions
should reflect consideration of current guidelines. Lifestyle
modification should be exhausted before ablative therapy is
decided.
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